The World Health Organization, WHO, has stated that Nigeria will be part of the clinical trials of the vaccines which are being developed to combat COVID-19.
This was disclosed by the head of WHO in Nigeria, Fiona Braka, while speaking at the Presidential Task Force on COVID-19 press briefing in Abuja.
She also revealed that about a 100 countries have expressed interest in the vaccines.
She stated, “Nigeria has also expressed interest to be part of this solidarity trial and efforts are underway to start the process in Nigeria too,” Braka said.
“Together with global health actors and partners, over the past week, WHO launched the access to COVID-19 tools ACT accelerator, a global collaboration to accelerate development for equitable access to new COVID-19 diagnostics, therapeutics and vaccines.
“We have a total of 89 vaccines that are in development globally, including seven in clinical evaluation and several therapeutics are in clinical trials. WHO is committed to ensuring that as medicines and vaccines are developed, they are shared equitably with all countries and people.
“We do have the solidarity trial which is an international clinical trial to help find an effective treatment for COVID-19, launched by the WHO and partners. More than 100 countries have joined the solidarity trial and to date, over 1,200 patients have been randomized from the first five countries to evaluate the safety and efficacy of full drug and drug combinations.”
- COVID-19: Nigeria To Begin Clinical Trials Of Dexamethasone – Minister
- COVID-19 vaccines now in phase 3 clinical trials — WHO
- First human clinical trials involving a bionic eye set to begin
- COVID-19: FG okays 5 states, FCT for WHO’s clinical trials
- Madagascar starts COVID-Organics clinical trials, factory to be built
- WHO to resume chloroquine coronavirus clinical trials
- COVID-19: Ooni, Afe Babalola University partner on clinical research for drugs, vaccines
- COVID-19 vaccines now in phase 3 clinical trial– WHO
- Dexamethasone: Nigeria to begin a clinical trial
- COVID-19: Clinical tests begin for German-U.S Coronavirus vaccine